Literature DB >> 27385782

Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG.

Bruce D Wines1, Hillary A Vanderven2, Sandra E Esparon3, Anne B Kristensen2, Stephen J Kent4, P Mark Hogarth5.   

Abstract

Ab-dependent cellular cytotoxicity, phagocytosis, and Ag presentation are key mechanisms of action of Abs arising in vaccine or naturally acquired immunity, as well of therapeutic mAbs. Cells expressing the low-affinity FcγRs (FcγRII or CD32 and FcγRIII or CD16) are activated for these functions when receptors are aggregated following the binding of IgG-opsonized targets. Despite the diversity of the Fc receptor proteins, IgG ligands, and potential responding cell types, the induction of all FcγR-mediated responses by opsonized targets requires the presentation of multiple Fc regions in close proximity to each other. We demonstrated that such "near-neighbor" Fc regions can be detected using defined recombinant soluble (rs) dimeric low-affinity ectodomains (rsFcγR) that have an absolute binding requirement for the simultaneous engagement of two IgG Fc regions. Like cell surface-expressed FcγRs, the binding of dimeric rsFcγR ectodomains to Ab immune complexes was affected by Ab subclass, presentation, opsonization density, Fc fucosylation, or mutation. The activation of an NK cell line and primary NK cells by human IgG-opsonized influenza A hemagglutinin correlated with dimeric rsFcγRIIIa binding activity but not with Ab titer. Furthermore, the dimeric rsFcγR binding assay sensitively detected greater Fc receptor activity to pandemic H1N1 hemagglutinin after the swine influenza pandemic of 2009 in pooled human polyclonal IgG. Thus these dimeric rsFcγR ectodomains are validated, defined probes that should prove valuable in measuring the immune-activating capacity of IgG Abs elicited by infection or vaccination or experimentally derived IgG and its variants.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27385782     DOI: 10.4049/jimmunol.1502551

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

2.  HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Authors:  Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

3.  Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.

Authors:  Jean-Louis Palgen; Nicolas Tchitchek; André Rodriguez-Pozo; Quentin Jouhault; Hadjer Abdelhouahab; Nathalie Dereuddre-Bosquet; Vanessa Contreras; Frédéric Martinon; Antonio Cosma; Yves Lévy; Roger Le Grand; Anne-Sophie Beignon
Journal:  NPJ Vaccines       Date:  2020-03-19       Impact factor: 7.344

4.  Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Authors:  Wen Shi Lee; Anne B Kristensen; Thomas A Rasmussen; Martin Tolstrup; Lars Østergaard; Ole S Søgaard; Bruce D Wines; P Mark Hogarth; Arnold Reynaldi; Miles P Davenport; Sean Emery; Janaki Amin; David A Cooper; Virginia L Kan; Julie Fox; Henning Gruell; Matthew S Parsons; Stephen J Kent
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

5.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

6.  Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells.

Authors:  Sai Priya Anand; Jérémie Prévost; Sophie Baril; Jonathan Richard; Halima Medjahed; Jean-Philippe Chapleau; William D Tolbert; Sharon Kirk; Amos B Smith; Bruce D Wines; Stephen J Kent; P Mark Hogarth; Matthew S Parsons; Marzena Pazgier; Andrés Finzi
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 7.  Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.

Authors:  Sinthujan Jegaskanda; Hillary A Vanderven; Adam K Wheatley; Stephen J Kent
Journal:  Hum Vaccin Immunother       Date:  2017-03-23       Impact factor: 3.452

8.  Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques.

Authors:  Matthew S Parsons; Wen Shi Lee; Anne B Kristensen; Thakshila Amarasena; Georges Khoury; Adam K Wheatley; Arnold Reynaldi; Bruce D Wines; P Mark Hogarth; Miles P Davenport; Stephen J Kent
Journal:  J Clin Invest       Date:  2018-11-26       Impact factor: 14.808

9.  Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors.

Authors:  Chen S Tan; Joshua Ghofrani; Emma Geiger; Igor J Koralnik; Stephanie Jost
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

10.  Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB.

Authors:  Richard J Stopforth; Robert J Oldham; Alison L Tutt; Patrick Duriez; H T Claude Chan; Brock F Binkowski; Chad Zimprich; Dun Li; Philip G Hargreaves; Mei Cong; Venkat Reddy; Maria J Leandro; Geraldine Cambridge; Anja Lux; Falk Nimmerjahn; Mark S Cragg
Journal:  J Immunol       Date:  2018-01-19       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.